Trends in PCSK9 Inhibitor Prescriptions before and after the Price Reduction in Patients with Atherosclerotic Cardiovascular Disease.
Alex SmithDrew M JohnsonJoshua BanksScott W KeithDean G KaralisPublished in: Journal of clinical medicine (2021)
Despite the reduction in the cost of PCSK9 inhibitors, most eligible patients are not prescribed one. The reduction in cost has improved adherence, primarily in patients with commercial insurance. Older patients and those on Medicare still face significant barriers in accessing a PCSK9 inhibitor. Further reductions in the price of the PCSK9 inhibitors are needed as is further study of the barriers that exist in prescribing one.
Keyphrases
- cardiovascular disease
- low density lipoprotein
- end stage renal disease
- newly diagnosed
- ejection fraction
- primary care
- peritoneal dialysis
- healthcare
- prognostic factors
- metabolic syndrome
- adipose tissue
- coronary artery disease
- cardiovascular risk factors
- skeletal muscle
- cardiovascular events
- insulin resistance
- patient reported